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Regulation of the renal circulation
JAY H. STEIN
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It is a great pleasure for me to participate in honoring my
mentor, Dr. Donald W. Seldin. When I began my fellowship in
Dallas in 1967, the field of renal physiology was booming.
Laboratories all over the world were beginning to unravel the
puzzle of sodium handling by the nephron and Seldin was one of
the main catalysts. From this intellectual experience in Dallas,
I spent the next decade or so studying the renal circulation, its
effect on sodium transport, and various humoral factors that
play a role in the regulation of renal resistance. It's incredible
how much our knowledge has changed in these 23 years. I first
heard of prostaglandins in 1968 at one of the weekly sessions in
Dallas from a visiting professor. Renal autoregulation was
poorly understood and few incisive experimental studies had
been done. The kinin system was just beginning to emerge and
obviously no one had heard of atrial natriuretic peptide or
endothelin.
In this brief article, I'd like to review two facets of the renal
circulation: autoregulation and various humoral agents which
regulate renal vasomotor tone. Because of space constraints,
this will be quite brief and I would refer interested readers to a
more extensive review of the subject by Dr. Claudia Hura and
myself [1].
Autoregulation
In the past 15 to 20 years, various researchers beginning with
Brenner and his group, have quantified segmental vascular
resistance in the steady state and during various experimental
maneuvers such as a reduction in renal perfusion pressure [21.
Most of our information on renal vascular resistance comes
from micropuncture data in dogs and rats. Hydrostatic pressure
decreases by a finite and significant amount between the renal
artery and glomerular capillaries. This pressure drop was
initially presumed to be due primarily to resistance changes in
the afferent arteriole. In the anesthetized rat, afferent arteriolar
resistance has been reported to be responsible for 60% of the
total renal vascular resistance [3, 4]. Data from the dog is more
variable, suggesting that the afferent arteriolar contribution to
total renal vascular resistance varies from 40 to 60% [5, 6].
There is also recent evidence in the rat to suggest that the
interlobular artery may contribute a significant amount to
preglomerular vascular resistance [7]. These studies suggest
that vessels proximal to the afferent arteriole contribute 26% of
the total renal vascular resistance. This has not been found to
be true in the dog [8]. Data obtained from the rat suggests that
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efferent arteriolar resistance constitutes approximately 30% of
total renal vascular resistance [3, 4, 9, 10]. With these basic
data, let's now turn to autoregulation.
It appears that renal blood flow autoregulation is mediated
primarily by resistance changes in the afferent arteriole [4].
Efferent arteriolar resistance changes little until perfusion pres-
sure falls below 80 mm Hg. These renal vascular autoregulatory
changes occur within one second of the change in perfusion
pressure and are usually complete within 15 to 20 seconds [11].
Currently, there are two mechanisms which may explain
renal autoregulation. They are the distal tubular feedback
hypothesis (tubuloglomerular feedback) and the myogenic hy-
pothesis.
Distal tubular feedback hypothesis
Originally described by Thurau and Schnermann, the distal
tubular feedback hypothesis or tubuloglomerular feedback re-
lates the composition of distal tubular fluid to changes in renal
vascular resistance and glomerular filtration rate in that partic-
ular nephron [12]. However, the majority of studies indicate
that tubuloglomerular feedback is not the mechanism responsi-
ble for renal blood flow autoregulation.
For example, Kaliskog et al studied interlobular arteries that
reached the surface of the rat kidney and found that these
vessels were capable of autoregulation when perfusion pressure
was decreased [13]. The authors concluded that since the
macula densa was not anatomically related to the interlobular
artery, it was unlikely that a distal tubular feedback mechanism
was responsible for autoregulatory behavior at least in this
species. Further, Young and Marsh evaluated the time course
of autoregulation following rapid changes in renal perfusion
pressure [11]. They found that autoregulatory changes occurred
before the changes in distal tubular fluid composition could
occur. Thus, other mechanisms must exist to explain renal
blood flow autoregulation.
Myogenic theory
This theory was originally proposed by Bayliss based on
blood flow autoregulatory studies in the dog and cat hind limb
[14]. LaPlace's law states that T = R(PV — PEV) where T is the
wall tension, R is the vessel radius, Pv is the intravascular
hydraulic pressure and P, is the extravascular hydraulic
pressure. Assuming that vessel wall tension is to be maintained
constant, changes in transmural pressure would result in in-
verse changes in vessel radius.
A number of findings support a role for the myogenic theory
in renal autoregulation. First, infusion of papaverine which
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caused smooth muscle paralysis, abolishes autoregulation [15].
Second, the rapidity of vascular resistance changes after
changes in renal perfusion pressure (one to three seconds) is
compatible with a myogenic response.
Studies by Gilmore et al on renal tissue transplanted to the
hamster cheek pouch provide direct evidence for myogenic
autoregulation [16]. A rise in chamber pressure resulted in
increased cheek pouch interstitial pressure and an increase in
afferent arteriolar radius. Interstitial pressure changes had no
effect on the efferent arteriole. Finally, Edwards studied iso-
lated afferent and efferent arterioles of the rabbit [17]. Afferent
arterioles exhibited appropriate autoregulatory behavior in re-
sponse to incremental changes in intravascular pressure, while
efferent arterioles did not. Thus, current data would seem to
indicate that renal blood flow autoregulation is mediated pri-
marily by an intrinsic myogenic mechanism at the level of the
afferent arteriole.
Vasoactive substances
Renin-angiotensin system (RAS)
Exogenous infusions of angiotensin II (Ang II) have been
shown to decrease renal blood flow in both man [18] and
experimental animals [19, 20]. Glomerular filtration rate is
reduced, but to a lesser extent resulting in an increase in the
filtration fraction [21, 22]. Micropuncture studies employing
exogenous administration of Ang II have demonstrated reduc-
tion in glomerular plasma flow and single nephron glomerular
filtration rate [23, 24]. Studies in the rat have shown an Ang
Il-induced decrease in the ultrafiltration coefficient [23].
Experimental efforts have also concentrated on the study of
the renin-angiotensin system as a local regulatory system and
on the possibility that intrarenally formed Ang II acts to
modulate renal vascular tone. Studies using immunohistochem-
ical techniques have confirmed the intrarenal location of the
components of the renin-angiotensin system [25, 26]. The
substantial quantity of angiotensin converting enzyme present
in interstitial and intravascular locations in the kidney could
convert both intrarenally generated Ang I and systemically
delivered Ang I to Ang II [27, 28]. Various techniques have
estimated the intrarenal conversion rate of systemically deliv-
ered Ang I to Ang II to be between 1 and 20% [29—3 1].
Measured Ang II concentrations in renal lymph are over 100
times greater than plasma levels [32] and approximately 10-fold
higher than in renal blood [33, 34]. These data suggest the
kidney is capable of synthesizing Ang II in quantities sufficient
to have local effects on renal hemodynamics.
The effects of the intrarenal RAS has been investigated using
several techniques. Converting enzyme inhibitors have been
infused intrarenally to block the formation of endogenous Ang
II. The response observed in the kidney is dependent on the
pre-existing level of activation of the RAS. Thus, to maximize
the renal response to angiotensin blockade, prior activation of
the RAS has been experimentally achieved using a low sodium
diet or a reduction of renal artery pressure. There seems to be
general agreement that in such models where the renin-angio-
tensin system has been previously activated, Ang II blockade
results in an increase in renal blood flow [35—37].
The controversy regarding the role of Ang II in renal blood
flow autoregulation has been studied in many laboratories. The
majority of experimental data using infusions of Ang II, infu-
sions of Ang II antagonists, or chronic renin depletion models
have not supported a role for the renin-angiotensin system in
the autoregulation of renal blood flow [38—40].
Micropuncture studies in dogs and rats have also suggested
that Ang II is capable of both afferent and efferent arteriolar
vasoconstriction [23, 37]. In the split hydronephrotic kidney
preparation, Ang II infusion caused vasoconstriction of both
afferent and efferent arterioles [41, 42]. Both afferent and
efferent vasoconstriction in response to Ang II was also dem-
onstrated in the blood-perfused juxtamedullary nephron prepa-
ration [43]. In isolated rabbit afferent and efferent arterioles
statically perfused in vitro, Ang II produced only efferent
vasoconstriction with no apparent effect on the afferent arteri-
ole [17].
Some of the conflicting data regarding the influence of Ang II
on segmental vascular resistance in the kidney needs to be
interpreted in view of the multiple potential interactions be-
tween Ang II and other vasoactive and hormonal systems. Ang
II is felt to enhance adrenergic activity by increasing norepi-
nephnne release at the neuroeffector junction [44, 45]. Con-
versely, renal nerve stimulation increases the release of renin
by the kidney [46].
Recent studies have also suggested an interaction between
Ang II and adenosine in controlling aft'erent arteriolar resis-
tance. The studies indicate that the presence of Ang II is
necessary for adenosine-induced renal vasoconstriction [47].
Conversely, high levels of adenosine may alter the responsive-
ness of afferent arterioles to Ang II by uncovering a potent
constrictor response to Ang II [48]. Finally, vasodilatory pros-
taglandins may act to modify the renal vascular response to Ang
II.
In summary, currently available data suggest that both
endogenous and exogenous Ang II influence renal hemodynam-
ics. While Ang II has been clearly shown to be capable of
causing vasoconstriction in afferent arterioles, its primary phys-
iologic action appears to be on the efferent arteriole.
Vasopressin
Vasopressin may play a role in the control of renal blood flow
but the magnitude and direction of its influence is unclear.
Exogenous infusion of vasopressin in low doses has been
reported to cause an increase in renal blood flow [49]. The
intrarenal administration of high dose AVP (approximately 20
ng/kg/min) has produced renal vasoconstriction and a decline in
renal blood flow in some studies [50, 51], while other investi-
gators have failed to demonstrate any effects on total renal
blood flow [52]. The reason for these conflicting results is
unclear, but may be due in part to varying doses of vasopressin,
varying states of fluid balance in the animals used, and the
influence of other modulating vasoactive agents, such as pros-
taglandins.
The influence of vasopressin on regional renal blood flow has
been examined. It was proposed that since increased medullary
blood flow tends to wash out solute from the medulla, a
decrease in medullary blood flow should increase renal concen-
trating ability. Therefore, ADH could augment medullary to-
nicity by selectively reducing medullary blood flow. This hy-
pothesis was initially supported by a number of studies [53, 54].
The most recent examination of the question by Zimmer-
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hacki, Robertson and Jamison has employed the videomicro-
scopic technique and specific V1 and V2 receptor antagonists in
the rat [55]. In these studies, the transition from diuresis to
antidiuresis was associated with a decrease in medullary blood
flow. Infusion of physiologic doses of AVP resulted in vasocon-
striction of the vasa recta which was partially blocked by a V1
receptor antagonist. Administration of a V2 antagonist restored
medullary blood flow to values seen in water diuresis. Selective
inhibition of AVP-induced papillary vasoconstriction with a V1
receptor antagonist did not influence urinary concentrating
ability. Thus, it would seem that the effects of AVP on
medullary blood flow are not necessary for its antidiuretic effect
and may be a consequence rather that the cause of alterations in
urinary concentrating and diluting mechanisms.
Adenosine
Adenosine, a nucleoside product of adenosine triphosphate
(ATP) hydrolysis is felt to play a role in the control of renal
blood flow and glomerular filtration [56].
The intrarenal infusion of adenosine produces a short-lived,
dose-related reduction in renal blood flow of approximately one
to four minutes duration. This is followed by a return to
baseline or slightly elevated levels of blood flow [47, 56]. When
the adenosine infusion is stopped, blood flow rate may tran-
siently increase even further [57]. Chronic administration of
adenosine over a period of days to conscious dogs results in a
dose-related vasodilation [58]. Glomerular filtration rate and
filtration fraction are decreased for the duration of adenosine
infusion, regardless of the effect on total renal blood flow.
The effects of adenosine on the renal microcirculation have
also been examined. Tagawa and Vander calculated arteriolar
resistance changes in dogs receiving intrarenal adenosine infu-
sions and reported afferent arteriolar vasoconstriction and
efferent arteriolar vasodilation [59]. Micropuncture studies per-
formed in dogs during intrarenal adenosine infusion demon-
strated vasoconstriction of superficial cortical afferent arteri-
oles at a time when total renal blood flow had stabilized [57].
However, Hall, Granger and Hester calculated serial changes in
vascular resistance and demonstrated an initial increase in
afferent arteriolar resistance which fell to control levels as total
renal blood flow returned to or exceeded baseline values [47]. In
isolated canine afferent arterioles statically perfused in vitro,
2-chloroadenosine, a non-selective, nonmetabolized adenosine
analog, produced short-lived vasoconstriction of 3 to 10 min-
utes duration despite continued presence of the 2-chloradeno-
sine [60]. No change in the glomerular ultrafiltration coefficient
has been noted with adenosine infusion [57].
Arend, Thompson and Spielman studied the effects of dipyr-
idamole, an adenosine uptake blocker [61]. They demonstrated
that dipyridamole administration elevated renal adenosine lev-
els, and that GFR declined in sodium-depleted but not sodium-
loaded dogs. This decline in GFR was inhibited by theophylline.
Hall and colleagues found that infusion of the converting
enzyme inhibitor SQ 14225 almost completely abolished adeno-
sine-mediated vasoconstriction, while infusion of angiotensin II
restored the vasoconstrictor response to adenosine in dogs
treated with SQ14225 [47]. When angiotensin is infused with
adenosine, the initial vasoconstrictor response is prolonged.
Afferent arteriolar resistance remains elevated during the entire
infusion, however, despite the return of renal blood flow to
normal [48]. Adenosine may alter the responsiveness of the
afferent arteriole to angiotensin II by uncovering a potent
constrictor response.
In summary, the renal effects of adenosine are very complex,
but more and more data are accumulating indicating that this
metabolite may be a very important regulator of renal vascular
tone.
Prostaglandins
While the role of prostaglandins in the control of basal or
resting blood flow is felt to be insignificant [62] prostaglandins
do seem to play a role as modulators of the renal vascular
effects of a number of vasoconstrictor hormones [63].
The effect of blockade of renal prostaglandin synthesis de-
pends on the level of activation of other neurohumoral vasoac-
tive systems. In awake, sodium replete, unstressed animals, the
administration of cyclooxygenase inhibitors has essentially no
effect on renal blood flow or glomerular filtration rate [64].
However, in hypovolemic, anesthetized, or surgically operated
animals, cyclooxygenase inhibition results in increased renal
vascular resistance and decreased renal blood flow [64-66].
Situations where renal perfusion is reduced due to decreased
intravascular volume or a fall in effective blood volume are
associated with enhanced levels of angiotensin II, norepineph-
rime, and vasopressin. These neurohumoral agents have all been
associated with increased renal prostaglandin synthesis [67—69].
Thus clinical conditions where prostaglandins may play an
important role in modulating renal vascular resistance agents
include anesthesia and surgical stress [66], renal ischemia [70],
hemorrhagic hypotension [71], dehydration [71], congestive
heart failure [72], and cirrhosis [73].
Prostaglandins may also play a role in augmenting the renal
vasodilator response to other substances. Bradykinin, calcium
ionophore, and furosemide augment renal PGE2 synthesis
which may contribute, in part, to the vasodilator actions of
these agents [74—76].
During early ureteral obstruction, renal PGE2 production is
increased and contributes to the vasodilation seen [77]. The
later stages of ureteral obstruction are characterized by vaso-
constriction and increased levels of renal thromboxane A2
synthesis [77].
The administration of prostaglandin inhibitors does not alter
renal blood flow autoregulation [78].
In summary, it appears that prostaglandins act as local
regulators of renal vascular tone. They contribute little to renal
blood flow control in the resting state, but act to attenuate the
renal vascular response to a variety of vasoconstrictor sub-
stances.
Kinins
Bradykinin is the kinin released from plasma kallikrein.
Infusion of the kinin in dogs [79], normal human subjects [80],
or isolated perfused kidneys [81] result in marked renal vasodi.
latation. In isolated rabbit renal arterioles preconstricted with
norepinephrine, bradykinin caused a dose-dependent relaxation
of efferent arterioles with no effect on afferent arterioles [82].
A number of interactions has been described between the
kallikrein-kinin system, the renin-angiotensin system and pros-
taglandins that may influence the effect of the kinins on renal
blood flow. In the rat, aldosterone appears to stimulate kal-
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likrein synthesis and secretion [831. There is also some evidence
that angiotensin II may stimulate renal kallikrein release [84].
Prostaglandins stimulate and prostaglandin synthesis inhibitors
suppress renal kallikrein excretion [85]. Conversely, kinins
stimulate prostaglandin production by perfused dog and rabbit
kidneys [86, 871 and by blood vessels, including the renal artery
and renal microvessels [88—90].
Despite extensive work, the physiologic role of kinins as
regulators of renal blood flow remains to be clarified.
Atrial natriuretic peptide
Recently, a family of endogenous peptides with diuretic,
natriuretic, and vascular smooth muscle relaxant properties has
been identified [911. These peptides are released primarily from
the cardiac atria in response to volume expansion and have
been suggested to play a role in the control of sodium balance
[92].
ANP has been demonstrated to relax both nonvascular
smooth muscle and a variety of isolated vascular segments,
including the renal artery [93—95]. In both conscious and
anesthetized dogs, exogenous infusions of ANP have been
consistently reported to produce an increase in renal blood
flow, although this increase is frequently transient [96, 97].
Whole kidney filtration fraction showed consistent increases in
both in vivo [96, 98] and in vitro studies [99, 100]. In isolated
canine glomeruli perfused in vitro at constant pressure, infusion
of ANP produced significant increases in single nephron gb-
merular filtration rate, single nephron filtration fraction, and
gbomerular capillary pressure, but no change in glomerular flow
[100]. This is consistent with ANP-induced efferent arteriolar
vasoconsti-jction with or without afferent arteriolar vasodila-
tion. Yet, in rabbit superficial afferent and efferent arterioles,
statically perfused in vitro, ANP had no effect on arteriolar
lumen diameter both in the control state or in vessels pre-
constricted with norepinephrine or angiotensin II [101]. Further
work is obviously needed in this intriguing area.
Endothelin
As an example of the burgeoning field of new vasoactive
agents, one only has to look at endothelin. This compound was
first described in 1988 [1021 and since has taken on a life of its
own. It is an extraordinarily potent vasoconstrictor which can
cause a marked decline in glomerular filtration rate and renal
plasma flow and a reduction in the ultrafiltration coefficient
[103]. In some model systems, it can stimulate prostacyclin
[104], endothelial-derived relaxing factors such as nitric oxide
[104], and atrial natriuretic peptide [105], while at the same time
markedly reducing renin release [106]. Studies have clearly
suggested that this agent may be involved in the pathophysiol-
ogy of acute renal failure and, in fact, intrarenal infusion of an
anti-endothelin antibody markedly attenuates the reduction in
single nephron GFR observed after renal ischemia [107]. Thus,
we have another peptide which may in fact be involved in the
regulation of renal vascular tone.
Conclusion
Every important regulatory system has an array of forces that
may come into play to maintain homeostatic balance. This is
certainly true of the renal circulation which may explain, at
least in part, why Donald Seldin loves so much to talk about it.
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